Format

Send to

Choose Destination
Blood. 2009 Jun 4;113(23):5711-9. doi: 10.1182/blood-2008-10-143560. Epub 2009 Mar 18.

How we treat cytomegalovirus in hematopoietic cell transplant recipients.

Author information

1
Vaccine and Infectious Disease Institute and Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. mboeckh@fhcrc.org

Abstract

Cytomegalovirus (CMV) continues to cause major complications after hematopoietic cell transplantation (HCT). Over the past decade, most centers have adopted preemptive antiviral treatment or prophylaxis strategies to prevent CMV disease. Both strategies are effective but also have shortcomings with presently available drugs. Here, we review aspects of CMV treatment and prevention in HCT recipients, including currently used drugs and diagnostics, ways to optimize preemptive therapy strategies with quantitative polymerase chain reaction assays, the use of prophylaxis, management of CMV disease caused by wild-type or drug-resistant strains, and future strategies.

PMID:
19299333
PMCID:
PMC2700312
DOI:
10.1182/blood-2008-10-143560
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center